Company registration number 14058395 (England and Wales)
AGNOVOS HEALTHCARE UK LTD
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
AGNOVOS HEALTHCARE UK LTD
CONTENTS
Page
Director's report
1
Statement of comprehensive income
2
Balance sheet
3
Statement of changes in equity
4
Notes to the financial statements
5 - 8
AGNOVOS HEALTHCARE UK LTD
COMPANY INFORMATION
Director
James Howe
Company number
14058395
Registered office
5 Churchill Place, 10th Floor
London
United Kingdom
E14 5HU
AGNOVOS HEALTHCARE UK LTD
DIRECTOR'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The director presents his annual report and financial statements for the year ended 31 December 2024.

Principal activities

The principal activity of the company is that of a medical technology company.

Director

The director who held office during the year and up to the date of signature of the financial statements was as follows:

James Howe
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
James Howe
Director
25 September 2025
AGNOVOS HEALTHCARE UK LTD
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
2024
2023
Notes
£
£
Cost of sales
3,113
72,468
Administrative expenses
(125,217)
(21,203)
Other operating income
129,896
23,630
Profit before taxation
7,792
74,895
Tax on profit
4
-
0
-
0
Profit for the financial year
7,792
74,895

The profit and loss account has been prepared on the basis that all operations are continuing operations.

AGNOVOS HEALTHCARE UK LTD
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 3 -
2024
2023
Notes
£
£
£
£
Current assets
Stocks
5
77,825
87,164
Debtors
6
99,209
162
Cash at bank and in hand
66,111
-
0
243,145
87,326
Creditors: amounts falling due within one year
7
(237,863)
(89,836)
Net current assets/(liabilities)
5,282
(2,510)
Capital and reserves
Called up share capital
8
1
1
Profit and loss reserves
5,281
(2,511)
Total equity
5,282
(2,510)

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 25 September 2025
James Howe
Director
Company registration number 14058395 (England and Wales)
AGNOVOS HEALTHCARE UK LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
Share capital
Profit and loss reserves
Total
£
£
£
Balance at 1 January 2023
1
(77,406)
(77,405)
Year ended 31 December 2023:
Profit and total comprehensive income
-
74,895
74,895
Balance at 31 December 2023
1
(2,511)
(2,510)
Year ended 31 December 2024:
Profit and total comprehensive income
-
7,792
7,792
Balance at 31 December 2024
1
5,281
5,282
AGNOVOS HEALTHCARE UK LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -
1
Accounting policies
Company information

Agnovos Healthcare UK Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 5 Churchill Place, 10th Floor, London, United Kingdom, E14 5HU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention.

1.2
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.3
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

AGNOVOS HEALTHCARE UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 6 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.4
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.5
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.6
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
-
0
AGNOVOS HEALTHCARE UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
4
Taxation

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit before taxation
7,792
74,895
Expected tax charge based on the standard rate of corporation tax in the UK of 19.00% (2023: 19.00%)
1,480
14,230
Tax effect of utilisation of tax losses not previously recognised
(1,480)
-
0
Unutilised tax losses carried forward
-
0
(14,230)
Taxation charge for the year
-
-
5
Stocks
2024
2023
£
£
Stocks
77,825
87,164
6
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
75,165
-
0
Other debtors
24,044
162
99,209
162

The debtor obligations disclosed in the financial statements represent amounts owed to an affiliate entity.

7
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
69,529
81,981
Amounts owed to group undertakings
153,852
3,922
Other creditors
14,482
3,933
237,863
89,836
AGNOVOS HEALTHCARE UK LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
8
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
of £1 each
1
1
1
1
9
Parent company

The entire issued share capital of Agnovos Healthcare UK Ltd is held by AgNovos Healthcare GmbH, a company incorporated and registed in Switzerland.

 

The company's ultimate parent undertaking and controlling party is AgNovos Healthcare LLC (Delaware).

 

2024-12-312024-01-01falseCCH SoftwareCCH Accounts Production 2024.100James HowefalsefalseAudit exempt2025-09-25Audit exempt140583952024-01-012024-12-3114058395bus:Director12024-01-012024-12-3114058395bus:RegisteredOffice2024-01-012024-12-31140583952024-12-31140583952023-01-012023-12-3114058395core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3114058395core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31140583952023-12-3114058395core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3114058395core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3114058395core:CurrentFinancialInstruments2024-12-3114058395core:CurrentFinancialInstruments2023-12-3114058395core:ShareCapital2024-12-3114058395core:ShareCapital2023-12-3114058395core:RetainedEarningsAccumulatedLosses2024-12-3114058395core:RetainedEarningsAccumulatedLosses2023-12-3114058395core:ShareCapital2022-12-3114058395core:RetainedEarningsAccumulatedLosses2022-12-3114058395core:UKTax2024-01-012024-12-3114058395core:UKTax2023-01-012023-12-3114058395core:WithinOneYear2024-12-3114058395core:WithinOneYear2023-12-3114058395bus:PrivateLimitedCompanyLtd2024-01-012024-12-3114058395bus:FRS1022024-01-012024-12-3114058395bus:AuditExempt-NoAccountantsReport2024-01-012024-12-3114058395bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP